Salvage Treatment After Failure or Relapse Following Initial Chemotherapy for Follicular Non-Hodgkin's Lymphoma

References

• Davidge‐Pitts M., Dansey R., Bezwoda W. R. Prolonged survival in low grade NHL is predicted by achievement of complete remission with initial treatment: results of a long term study with multivariate analysis of prognostic factors, In press
   Google Scholar
• National Cancer Institute sponsered study of the classification of non‐Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. The Non‐Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1993; 49: 2112–35
   Google Scholar
• Armitage J. O. Treatment of non‐Hodgkin's lymphoma. New England Journal of Medicine 1993; 328: 1023–1030
   PubMed Web of Science ®Google Scholar
• Straus D. J., Filipu D. A., Lieberman P. H., Koziner B., Thaler H. D., Clarkson B. D. The non‐Hodgkin's Lymphomas: I. A retrospective clinical and pathological analysis of 499 cases diagnosed between 1958–1969. Cancer 1983; 51: 101–109
   PubMed Web of Science ®Google Scholar
• Homing S. J. Low grade lymphoma 1993: State of the art. Annual Oncology (Suppl 5) 1994; 2: 523–527
   Google Scholar
• Meller G. E., Nathwani B. M., Buk J. S. Morphologic subclassification of follicular lymphoma variablility of diagnosis among histopathologists, a collaborative study between the repository centre and pathology panel for clinical lymphoma studies. Journal of Clinical Oncology 1985; 3: 25–38
   PubMedGoogle Scholar
• Medeiros J., Van Krieken J. H., Jaffe E. S., Raffeld M. Association of bcl‐1 rearrangements with lymphocytic lymphoma of intermediate differentiation. Blood 1990; 76: 2086–2090
   PubMed Web of Science ®Google Scholar
• Hockenberry D., Nûnez G., Millman C., Schreibet R. D., Korsmeyer S. J. BcI‐2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334
   PubMed Web of Science ®Google Scholar
• LoCoco F., Gaidano G., Loue D. C., Offik K., Chaganti R. S. K., Dalla‐Favera R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 82: 2289–2295
   PubMed Web of Science ®Google Scholar
• Baron B. W., Nucifora G., McCabe N., Espinosa R., Le Beau M. M., McKeithan. Indentification of the gene associated with the recurring chromosomal translocation t(3:14)(q27:q32) and t(3:22)(q17:q11) in B‐cell lymphomas. Procedure of natural academy of science, USA 1995; 90: 5262–5266
   Web of Science ®Google Scholar
• Jaffe E. S., Raffeld M., Medeiros L. J., Statler‐Stevenson M. An overview of the classification of non‐Hodgkin's lymphomas: an integration of morphological and phenotypical concepts. Cancer Research 1992; 52: 5447–5452, Suppl
   PubMed Web of Science ®Google Scholar
• Croc C. M. Molecular biology of lymphomas. Seminar in Oncology 1993; 20: 31–47
   Web of Science ®Google Scholar
• Ainenberg A. C. Utility of gene rearrangments in lymphoid malignancies. Annual Review of Medicine 1993; 44: 75–84
   PubMed Web of Science ®Google Scholar
• Carbone A., Pinto A., Gloghini A., Volpe R., Zagonel V. B‐zone lymphocytic lymphoma: a morphologic. immunophenotypic and clinical study with comparison to ‘well differentiated’ lymphocytic lymphoma. Human Pathology 1992; 23: 438–448
   PubMed Web of Science ®Google Scholar
• Gallacher C. T., Gregory W. M., Jones A. E., Stanfeld A. G., Richards M. A., Dhaliwal H. S., Malpas J. S., Lister T. A. Follicular lymphoma: prognostic factors for response and survival. Journal of Clinical Oncology 1986; 4: 1470–1480
   PubMed Web of Science ®Google Scholar
• Rudders K. A., Kaddis M., De Lellis R. A., Casey H., Jnr. Nodular non‐Hodgkin's lymphoma. Factors influencing prognosis and indications for aggressive treatment. Cancer 1979; 43: 1643–1651
   PubMed Web of Science ®Google Scholar
• Bittran J. C., Golombick H. M., Ultman J. E., Sweet K. L., Lester E. P., Stein R. S., Miller J. B., Morgan E. M., Kinnealy A. E., Vardiman J. E., Kinzie J., Roth N. O. Non‐Hodgkin's lymphoma, poorly differentiated and mixed cell types: results of sequential staging procedures, response to therapy and survey of 100 patients. Cancer 1978; 42: 88–95
   PubMed Web of Science ®Google Scholar
• Gospodarowicz M. G., Bush R. S., Brown T. C., Chua T. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. International Journal of Radiation Oncology, Biology and Physiology 1984; 10: 489–497
   PubMed Web of Science ®Google Scholar
• Cabanillas F., Smith T., Bodey C. P., Gutterman J. D., Freireich E. J. Nodular malignant lymphomas: factors affecting complete response and survival. Cancer 1979; 44: 1983–1989
   PubMed Web of Science ®Google Scholar
• Bastion Y., Berger F., Bryon P. P., Felman P., Ffrinch M., Coiffier B. Follicular lymphoma: assessment of prognostic factors in 127 patients followed for 10 years. Annuals of Oncology 1991; 2(Suppl 2)123–129
   PubMed Web of Science ®Google Scholar
• Romaghera J. E., McLauglin P., North L., Dixon D., Silvermintz K. B., Garnsey L. A., Velasquiez W. S., Hagemeister F. B., Cabanillas F. Multivariate analysis of prognostic factors in stage IV follicular low‐grade lymphomas: a risk mode. Journal of Clinical Oncology 1991; 9: 9762–9769
   Google Scholar
• Anderson T., DeVita V. T., Simon R. M., Berard C. W., Canellos G. P., Garvin A. J., Young R. C. Malignant lymphoma II. Prognostic factors and response to treatment of 473 patients at the National Cancer Institute. Cancer, 50: 2708–2721
   PubMed Web of Science ®Google Scholar
• Cabanillas F., Hagemeister F., Bodey G. P., Freireich E. J. Iphosphamide, methotrexate, VP16 (IMVP16) an effective salvage regimen for lymphoma. Blood 1982; 60: 693–697
   PubMed Web of Science ®Google Scholar
• Cabanillas F., Hagemeihter F. B., McLauglin P., Velaaques W. S., Riggs S., Fuller J., Smith T. Results of MIME salvage regimen for recurrent or refractory lymphoma. Journal of Clinical Oncology 1987; 5: 407–412
   PubMed Web of Science ®Google Scholar
• Bajetta E., Bason R., Valagussa P., Bonadonna G. Mitoxantrone an active agent in refractor non‐Hodgkin's lymphoma. American Journal of Clinical Oncology 1988; 11: 100–103
   PubMed Web of Science ®Google Scholar
• Buzzoni R., Colleoni M., Nelli P., Nolé F., Bajetta E. Results of a salvage regimen in refractory or relapsed non‐Hodgkin's lymphoma. Leukemia arid Lymphoma 1994; 14: 121–128
   PubMed Web of Science ®Google Scholar
• Brockman R. W., Schahel F. M., Jnr., Montgomery J. A. Biologic activity of 9‐β‐Darabinofuranosyl‐ 2 fluoroadenine, a metabolically stable analog of 9—Darabinofaranosyl‐adenine. Biochemistry and Pharmacology 1977; 26: 2193–2196
   PubMed Web of Science ®Google Scholar
• Redman J., Cabanillas G., Velasquez W., McLaughlin P., Hagenmeister F., Swan F., Rodriguez M., Plunkett W. K., Keating M. J. Phase II trial of fludarabine phosphate in lymphoma: an effective agent in low grade lymphoma. Journal of Clinical Oncology 1992; 10: 790–794
   PubMed Web of Science ®Google Scholar
• Lazarus H. M. Bone marrow transplantation in low‐grade non‐Hodgkin's lymphoma. Leukemia and Lymphoma 1995; 17: 199–210
   PubMed Web of Science ®Google Scholar
• Lepage E., Sebban D., Gisselbrecht C. Treatment of low‐grade non‐Hodgkin's lymphomas: assessment of dox‐orubicin in a controlled trial. Hematological Oncology 1990; 8: 31–38
   PubMed Web of Science ®Google Scholar
• Lopez‐Guillermo A., Montserrat E., Bosch F., Escoda L., Terol M. J., Marin P., Revertar J. C., Blade J., Cervantes F., Sierra J., Nomdedeu B., Urbano‐Ispizua A., Rouira M., Carreiras E., Canpo E., Rozman C. Low‐grade lymphoma: clinical and prognostic studies in a series of 143 patients from a single institution. Leukemia and Lymphoma 1994; 15: 159–165
   PubMed Web of Science ®Google Scholar
• Brandwein J. H., Smith A. M., Langley R. G., Burnell M., Sutcliffe S. B., Keating A. Outcome of patients with relapsed or refractory non‐Hodgkin's lymphoma referred for autologous bone marrow transplantation. Leukemia and Lymphoma 1991; 4: 231–238
   PubMed Web of Science ®Google Scholar
• Gribben J. G., Freedman A. S., Woo S. D. All advanced‐stage non‐Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl‐2 have residual cells containing the bcl‐2 rearrangement at evaluation after treatment. Blood 1991; 78: 3275–3280
   PubMed Web of Science ®Google Scholar
• Gribben J. G., Freedman A. S., Neuberg D. Immunologic paging of marrow assessed by PCR before autologous bone marrow transplantation for B‐cell lymphoma. New, England Journal of Medicine 1991; 325: 1525–1533
   PubMed Web of Science ®Google Scholar
• Rohatiner A. S., Freedman A., Nadler L. (1993) Myeloblative therapy with autologous transplantation as consolidation for follicular lymphoma. Procedures of the Fifth International Conference on Malignant Lymphoma, Lugao, June, 9–121993, Abstract 40
   Google Scholar
• Ried J. C., Kitada S., Takayama S., Miyashita T. Regulation of chemoresistance by the bcl‐2 oncoprotein in non‐Hodgkin's lymphoma and lymphocytic leukemia cell lines. Annals in Oncology 1994; 5(Suppl 1)561–565
   Google Scholar